Table 1.
Effects of pretreatment on the rise of airway basal tone (g) in human bronchi at peak or plateau post-stretch (5 minutes, 2
| Post-stretch peak | Post-stretch plateau | ||||
|---|---|---|---|---|---|
| Pretreatment | n | Control | Pretreated | Control | Pretreated |
| Epithelium removal | 12 | 1.43 ± 0.21 | 0.93 ± 0.15b | 1.38 ± 0.22 | 0.89 ± 0.16b |
| MK476 (0.1 μM) | 13 | 1.47 ± 0.19 | 0.89 ± 0.18a | 1.45 ± 0.19 | 0.61 ± 0.18b |
| Indomethacin (1 μM) | 9 | 1.25 ± 0.23 | 1.29 ± 0.23 | 1.21 ± 0.24 | 1.21 ± 0.21 |
| 1400 W (1 mM) | 11 | 1.19 ± 0.11 | 0.89 ± 0.14a | 1.13 ± 0.11 | 0.79 ± 0.16a |
| L-NAME (1 μM) | 9 | 1.16 ± 0.12 | 0.97 ± 0.29 | 1.09 ± 0.11 | 0.91 ± 0.29 |
| L-NAME (1 mM) | 13 | 1.37 ± 0.20 | 0.86 ± 0.16b | 1.31 ± 0.22 | 0.80 ± 0.16b |
| Nω-propyl-L-arginine (5 mM) | 11 | 1.19 ± 0.11 | 0.83 ± 0.09a | 1.13 ± 0.11 | 0.84 ± 0.10a |
| SR 140333 + SR 48968 + SR 142801 (0.1 μM each) |
9 | 1.01 ± 0.12 | 0.90 ± 0.16 | 0.96 ± 0.12 | 0.92 ± 0.17 |
| BQ 123 + BQ 788 (0.1 μM each) | 6 | 1.08 ± 0.16 | 1.20 ± 0.17 | 1.01 ± 0.14 | 1.17 ± 0.24 |
| Atropine (0.1 μM) | 9 | 1.23 ± 0.20 | 1.02 ± 0.22 | 1.16 ± 0.20 | 1.05 ± 0.22 |
| Gadolinium (0.1 mM) | 7 | 1.12 ± 0.11 | 0.98 ± 0.14 | 1.05 ± 0.12 | 0.95 ± 0.15 |
| Mepyramine (1 μM) | 9 | 1.15 ± 0.24 | 1.33 ± 0.20 | 1.11 ± 0.24 | 1.24 ± 0.23 |
| Y27632 (1 μM) | 7 | 1.12 ± 0.11 | 0.15 ± 0.07c | 1.05 ± 0.12 | 0.11 ± 0.05c |
Values are means ± standard error of the mean. aP < 0.05; bP < 0.01; cP < 0.001 vs. paired control. 1400 W, selective inhibitor of inducible nitric oxide synthase; BQ 123, selective endothelin ETA-receptor antagonist; BQ 788, selective endothelin ETB-receptor antagonist; L-NAME, L-nitroarginine methyl ester; MK476, leukotriene Cyst-LT1 receptor antagonist; SR 140333, tachykinin NK1-receptor antagonist; SR 48968, tachykinin NK2-receptor antagonist; SR 142801, tachykinin NK3-receptor antagonist; Y27632, selective Rho-kinase (ROCK1 and ROCK2) inhibitor.